Innovent Biologics (HK:1801) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innovent Biologics has received approval from China’s National Medical Products Administration for its drug Dovbleron, a next-generation treatment for ROS1-positive non-small cell lung cancer. This marks the 13th addition to Innovent’s portfolio, highlighting the company’s commitment to innovative cancer therapies. The approval follows positive results from a pivotal Phase 2 trial, showcasing significant efficacy in patients.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.